Takeda Pharmaceutical Co Ltd (4502.T)
Thu, Feb 22 2018
BRIEF-Riken Vitamin says Takeda Pharmaceutical to decrease voting power in co to 5.4 pct from 12.6 pct
* Says Takeda Pharmaceutical Co Ltd will decrease voting power in the company to 5.4 percent(881,760 shares) from 12.6 percent(2.1 million shares), effective Feb. 27
BRIEF-Wave Life Sciences And Takeda Form Strategic Collaboration To Advance Therapies For Central Nervous System Disorders
* WAVE LIFE SCIENCES AND TAKEDA FORM GLOBAL STRATEGIC COLLABORATION TO ADVANCE THERAPIES FOR CENTRAL NERVOUS SYSTEM DISORDERS
* Hikes full-year op profit outlook to 219 bln yen from 200 bln
TOKYO, Feb 1 Takeda Pharmaceutical Co Ltd , Japan's largest drugmaker by sales, on Thursday reported an almost 60 percent jump in quarterly operating profit and raised its annual forecast, citing stronger sales of cancer drug Velcade.
Japan's Takeda Pharmaceutical Co Ltd said on Monday the U.S. Food and Drug Administration had granted 'fast track' status to its vaccine for the mosquito-borne Zika virus, which erupted as a major public hazard in Brazil three years ago.
Jan 29 Japan's Takeda Pharmaceutical Co Ltd said on Monday the U.S. Food and Drug Administration had granted 'fast track' status to its vaccine for the mosquito-borne Zika virus, which erupted as a major public hazard in Brazil three years ago.
* TAKEDA’S ZIKA VACCINE CANDIDATE RECEIVES U.S. FDA FAST TRACK DESIGNATION
* EUROPEAN COMMISSION APPROVES ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA AFTER ONE PRIOR SYSTEMIC THERAPY– PROVIDING AN INNOVATIVE TREATMENT OPTION TO PATIENTS
* ARCTURUS THERAPEUTICS ANNOUNCES EXPANSION OF COLLABORATION WITH TAKEDA PHARMACEUTICALS TO DEVELOP RNA-BASED THERAPEUTICS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) AND OTHER GI DISORDERS
BRIEF-Takeda And Denali Therapeutics Collaborate To Develop Therapies For Neurodegenerative Diseases
* TAKEDA AND DENALI THERAPEUTICS COLLABORATE TO DEVELOP AND COMMERCIALIZE THERAPIES FOR NEURODEGENERATIVE DISEASES